2025-11-06
HC Andersen – Julie Waras Brogren
Julie Waras Brogren, Deputy CEO presents first half year 2025 highlights at HC Andersen
Presentations & Articles
2025-09-29
Redeye Interview – Magnus Corfitzen presents an update on Orviglance NDA and Financing
Magnus Corfitzen, CEO of Ascelia Pharma AB, discusses the NDA submission to the FDA for Orviglance and the recent SEK 30 million share issue Redeye Interview – 25 September 2025
2025-08-22
HC Andersen – Julie Waras Brogren
Julie Waras Brogren, Deputy CEO presents first half year 2025 highlights at HC Andersen
2025-05-19
HC Andersen – Julie Waras Brogren
Julie Waras Brogren, Deputy CEO presents first quarter 2025 highlights at HC Anderse
2025-05-13
ABGSC Investor Day
CEO Magnus Corfitzen presents at ABG Investor Day
2025-04-03
Interview with Andreas Norlin, CSO
Andreas Norlin, Chief Scientific Officer at Ascelia Pharma shares insights into the company’s latest developments and our plan for the NDA submission
2025-03-26
Ascelia Pharma Presentation
CEO Magnus Corfitzen presents at Økonomisk Ugebrev
2025-03-13
Carnegie – Healthcare Day
CEO Magnus Corfitzen presents at Carnegie Company Day.
2025-02-07
HC Andersen – Full year and Q4 2024 report with Julie Waras Brogren
HC Andersen - Q3 2024 report with Julie Waras Brogren
2025-01-29
Redeye Fight Cancer Event – January 22nd, 2025
Magnus Corfitzen, CEO at Ascelia Pharma AB presented at Redeye Fight Cancer Event
2025-01-29
HC Andersen – Julie Waras Brogren
HC Andersen - Q3 2024 report with Julie Waras Brogren
2024-11-13
HC Andersen – Q3 2024 report with Julie Waras Brogren
HC Andersen - Q3 2024 report with Julie Waras Brogren
2024-09-10
HC Andersen – Q&A with Magnus Corfitzen
Magnus Corfitzen, CEO presents at HC Andersen - Final outcome of Rights issue
2024-08-30
Carnegie – Company Day
CEO Magnus Corfitzen presents at Carnegie Company Day.
2024-08-22
Carnegie – Interview
CEO Magnus Corfitzen presents at Carnegie sharing insights on strong phase 3 results, rationale for the Rights issue 2024 and key milestones ahead
2024-08-22
Interview with Redeye
Magnus Corfitzen, CEO at Ascelia Pharma AB shared his insights on the timeline for the NDA submission of Orviglance and the ongoing Rights Issue.
2024-08-22
HC Andersen – Update on Q2 2024 and Rights issue
Julie Waras Brogren, Deputy CEO presents at HC Andersen
2024-08-13
HC Andersen Podcast – Business update
Magnus Corfitzen, CEOpresent at the HC Andersen Podcast